绥美凯进入医保了吗？

The English name is Triumeq, which consists of three drugs: dolutegravir 50mg (dolutegravir) + abacavir 0.6g (abacavir) + lamivudine 0.3g (lamivudine). It is suitable for adults and adolescents over 12 years old who are infected with human immunodeficiency virus (HIV) and weigh at least 40kg.

AIDS is a highly contagious and harmful disease of the human immune system, mainly caused by the HIV virus. Suimeike is currently the only three-in-one compound drug containing dolutegravir (DTG). It integrates treatment drugs for different stages of viral infection into the same tablet, and the therapeutic effect is very significant.

It is important to note that both abacavir and dolutegravir carry the risk of triggering a hypersensitivity reaction (HSR) and share some common characteristics, such as fever and/or rash and other symptoms indicating involvement of multiple organs. It is clinically impossible to determine whether abacavir or dolutegravir is responsible for a hypersensitivity reaction that occurs with Trimeq. Hypersensitivity reactions have been observed to occur more commonly with abacavir, some of which can be life-threatening and, in rare cases, fatal if not managed appropriately.

Suimeikai has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line treatment of choice for patients with newly diagnosed HIV infection. On January 22, 2018, the British multinational pharmaceutical company GlaxoSmithKline (GSK) announced that ViiV Healthcare, a joint venture of GSK, officially launched the innovative AIDS treatment drug Suimeikai in the Chinese market.

The price of original research drugs on the market in my country is usually relatively high, so many patients will ask: Is Suimeikan included in the medical insurance?

It is not yet covered by medical insurance, so patients need to purchase Suimeikai at their own expense at the original price. If patients want to buy the cheaper Suimeikan, they can choose the Indian version, which is produced by Emcure. Each box has 30 tablets and the price is around RMB 1,000. It may fluctuate due to factors such as exchange rates. Patients can consult the medical companion travel service for specific information.